Dan Scavilla'un ücretlendirmesi Globus Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$92m
Jun 30 2024	n/a	n/a	US$41m
Mar 31 2024	n/a	n/a	US$67m
Dec 31 2023	US$5m	US$464k	US$123m
Sep 30 2023	n/a	n/a	US$158m
Jun 30 2023	n/a	n/a	US$204m
Mar 31 2023	n/a	n/a	US$201m
Dec 31 2022	US$4m	US$437k	US$190m
Sep 30 2022	n/a	n/a	US$155m
Jun 30 2022	n/a	n/a	US$155m
Mar 31 2022	n/a	n/a	US$142m
Dec 31 2021	US$2m	US$396k	US$149m
Sep 30 2021	n/a	n/a	US$187m
Jun 30 2021	n/a	n/a	US$184m
Mar 31 2021	n/a	n/a	US$122m
Dec 31 2020	US$2m	US$384k	US$102m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$89m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$2m	US$366k	US$155m
Sep 30 2019	n/a	n/a	US$146m
Jun 30 2019	n/a	n/a	US$143m
Mar 31 2019	n/a	n/a	US$150m
Dec 31 2018	US$2m	US$355k	US$156m

Tazminat ve Piyasa: Dan 'nin toplam tazminatı ($USD 4.56M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.87M ).

Tazminat ve Kazançlar: Dan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Dan Scavilla (59 yo)

2.8yrs

Görev süresi

US$4,564,374

Tazminat

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Paul	Co-Founder & Executive Chairman	22yrs	US$3.22m	16.37% $ 1.8b
Daniel Scavilla	President	2.8yrs	US$4.56m	Veri yok
Keith Pfeil	CFO & COO	5.4yrs	US$2.06m	0% $ 0
Kelly Huller	Senior VP	6.1yrs	US$1.64m	0% $ 0
Brian Kearns	Senior Vice President of Business Development & Investor Relations	no data	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: GMED 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
David Paul	Co-Founder & Executive Chairman	22yrs	US$3.22m	16.37% $ 1.8b
Daniel Scavilla	President	2.8yrs	US$4.56m	Veri yok
Ann Rhoads	Independent Director	13.5yrs	US$490.69k	0.031% $ 3.5m
John DeFord	Independent Director	1.3yrs	US$276.27k	0.011% $ 1.3m
Stephen Zarrilli	Independent Director	5.7yrs	US$470.69k	0% $ 0
James Tobin	Independent Director	9.4yrs	US$478.19k	0% $ 0
Daniel Wolterman	Independent Director	1.3yrs	US$278.15k	0.018% $ 2.0m
Robert Douglas	Independent Director	5.1yrs	US$470.69k	0.0015% $ 165.6k
David Davidar	Independent Director	21.8yrs	US$468.19k	0.50% $ 56.4m
Leslie Norwalk	Independent Director	1.3yrs	US$278.77k	0.012% $ 1.4m
Daniel Lemaitre	Independent Director	13.8yrs	US$478.19k	Veri yok

5.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GMED 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/02 11:27
Gün Sonu Hisse Fiyatı	2025/01/02 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Globus Medical, Inc. 27 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Ishan Majumdar	Baptista Research
Matt Miksic	Barclays
Craig Bijou	BofA Global Research

Globus Medical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-Founder & Executive Chairman exercised options to buy US$2.2m worth of stock.

President notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Independent Director recently sold US$698k worth of stock

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Recent updates

Globus Medical, Inc. Launches ExcelsiusHub Navigation System

Co-Founder & Executive Chairman exercised options to buy US$2.2m worth of stock.

Globus Medical Stock: Re-Rated After A Solid Year

President notifies of intention to sell stock

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Globus Medical, Inc. Revises Earnings Guidance for the Full Year 2024

Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet

Independent Director notifies of intention to sell stock

Globus Medical, Inc. to Report Q3, 2024 Results on Nov 05, 2024

Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit

Globus Medical, Inc. Launches the Next Wave of Orthopedic Trauma Solutions

Independent Director notifies of intention to sell stock

Globus Medical: A Post Acquisition Analysis

Globus Medical, Inc. Launches ADIRA™? XLIF™? Plate System

Consensus EPS estimates fall by 46%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Globus Medical, Inc. Revises Earnings Guidance for the Year 2024

Globus Medical, Inc. Receives FDA 510(k) Clearance for Excelsiusflex™? and ACTIFY™? 3D Total Knee System

Globus Medical, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Value-Defensive Index

Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors

Price target increased by 7.8% to US$70.42

Independent Director recently sold US$698k worth of stock

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Director notifies of intention to sell stock

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Full year 2023 earnings: EPS misses analyst expectations

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical: Merger Overhang Lingering

Consensus EPS estimates fall by 32%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical: Almost Having My Back

New minor risk - Shareholder dilution

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical: Slightly Too Pricey Right Now

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Independent Director exercised options and sold US$1.4m worth of stock

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS misses analyst expectations

Globus Medical Q4 2022 Earnings Preview

Independent Director exercised options to buy US$334k worth of stock.

Price target decreased by 7.3% to US$72.58

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Investor sentiment deteriorates as stock falls 20%

Senior VP & CFO exercised options and sold US$760k worth of stock

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Independent Director exercised options to buy US$566k worth of stock.

Globus Medical: An Impressive Long-Term Revenue Growth Play

Insufficient new directors

Senior VP exercised options and sold US$468k worth of stock